Centiva Capital’s SpringWorks Therapeutics SWTX Stock Holding History

Centiva Capital’s Portfolio SWTX Stock Details SWTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-3,408	Closed	-$160K	–	1815
2025 Q2	$160K	Sell	3,408 -20,342	-86%	-$905K	﹤0.01%	1371
2025 Q1	$1.05M	Buy	+23,750	New	+$1.09M	0.03%	475
2023 Q2	–	Sell	-8,484	Closed	-$218K	–	1982
2023 Q1	$218K	Buy	+8,484	New	+$248K	0.01%	1197
2021 Q2	–	Sell	-13,037	Closed	-$959K	–	1614
2021 Q1	$959K	Sell	13,037 -796	-6%	-$62.3K	0.04%	381
2020 Q4	$1M	Buy	13,833 +9,366	+210%	+$603K	0.04%	273
2020 Q3	$213K	Buy	+4,467	New	+$190K	0.01%	576

Other funds holding SWTX

DekaBank Deutsche Girozentrale Frankfurt, Germany $59.2B AUM 26.02% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $20.6B AUM 34.61% 1-Year Est. Return

Centiva Capital's SWTX Position: Q3 2025 in Review

Centiva Capital sold out of SpringWorks Therapeutics (SWTX) in Q3 2025, closing a stake of 3,408 shares — an estimated $160K sold.

Centiva Capital first reported a position in SWTX in Q3 2020 and held it in 6 quarters. The position peaked at $1.05M in Q1 2025. 3 funds tracked by Wall St. Rank hold SWTX as of Q3 2025.

Centiva Capital reported no remaining SpringWorks Therapeutics position as of Q3 2025 after selling out during the quarter.
Centiva Capital sold 3,408 SpringWorks Therapeutics shares in Q3 2025, an estimated $160K.
Centiva Capital first reported a position in SpringWorks Therapeutics in Q3 2020 and held it in 6 quarters.
Centiva Capital's SpringWorks Therapeutics position peaked at $1.05M in Q1 2025.
3 funds tracked by Wall St. Rank held SpringWorks Therapeutics as of Q3 2025.

Based on Centiva Capital's 13F filing for Q3 2025, filed 14 Nov 2025.